The other six felt that closed-loop therapy did not confer exercise-related glucose benefits; the burdens described included experiencing hypoglycaemia despite using a temporary higher glucose target, delayed effects of insulin adjustment, and higher confidence with personally adjusting insulin dosing than the closed-loop algorithm. The gene discussed is INS; the disease is Hypoglycemia.